| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Trade names | iNCOVACC |
| Routes of administration | Intranasal |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| Part ofa series on the |
| COVID-19 pandemic |
|---|
 |
|
Medical response |
|
.svg) COVID-19 portal |
iNCOVACC (codenamedBBV154)[1] is anintranasalCOVID-19 vaccine candidate developed byBharat Biotech,[2][3] American company Precision Virologics[4][5] and theWashington University School of Medicine inSt Louis,Missouri, United States.[6][7]
On recommendation by the Subject Expert Committee (SEC) under the Indian drug regulator, the company conductedphase 1 clinical trials using 75 volunteers and submit safety andimmunogenicity data for the committee's consideration before it proceeds to the second phase of the trial.[8]
On 12 August 2021, after evaluating the results of phase I trial data, the drug regulator approved for phase II/III randomized trials that involves evaluation of the immunogenicity and safety ofCovaxin with BBV154 in healthy volunteers.[9]
On 24 December 2022, the Government of India approved the intranasal vaccine for inclusion in the vaccination programme as a booster dose for those above 18 years of age.[10][11]
| |||||||||||||
| Topics |
| ||||||||||||
| Incidents | |||||||||||||
| Locations |
| ||||||||||||
| Legal framework | |||||||||||||
| Agencies and institutes |
| ||||||||||||
| Officials |
| ||||||||||||
.png) | This article about COVID-19 vaccines is astub. You can help Wikipedia byexpanding it. |
 | This article aboutvaccines orvaccination is astub. You can help Wikipedia byexpanding it. |
